期刊文献+

Staging of hepatocellular carcinoma

原文传递
导出
摘要 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths in the world. In contrast to other cancers, survival of patients with HCC is determined by the extent of the tumor in addition to underlying liver disease and its functional reserve. From risk factors to management, HCC reveals a considerable geographic and institutional variation throughout the world. Although many staging and/or scoring systems have been proposed, each prognostic system has several benefits and limitations on its own. Therefore, there is currently no globally accepted system for HCC due to the extreme heterogeneity of the disease. In this review, currently available staging systems for assessing the prognosis of HCC, their uses, limitations, and future prospects are revisited.
出处 《Hepatoma Research》 2018年第9期93-110,共18页 肝癌研究(英文版)
  • 相关文献

参考文献2

二级参考文献109

  • 1JacquesFerlay,Hai‐RimShin,FreddieBray,DavidForman,ColinMathers,Donald MaxwellParkin.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int. J. Cancer . 2010 (12)
  • 2Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends inhepatocellular carcinoma incidence and mortality. Hepatology2014; 61: 191-199[PMID: 25142309 DOI: 10.1002/hep.27388].
  • 3El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinomain the United States: Where are we- Where do we go- Hepatology2014; 60: 1767-1775 [PMID: 24839253 DOI: 10.1002/hep.27222].
  • 4Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma:consider the population. J Clin Gastroenterol 2013; 47 Suppl:S2-S6 [PMID: 23632345 DOI: 10.1097/MCG.0b013e3182872f29].
  • 5Schütte K, Kipper M, Kahl S, Bornschein J, G-tze T, Adolf D,Arend J, Seidensticker R, Lippert H, Ricke J, Malfertheiner P.Clinical characteristics and time trends in etiology of hepatocellularcancer in Germany. Digestion 2013; 87: 147-159 [PMID: 23548687DOI: 10.1159/000346743].
  • 6Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA,Marrero JA. Meta-analysis: surveillance with ultrasound for earlystagehepatocellular carcinoma in patients with cirrhosis. AlimentPharmacol Ther 2009; 30: 37-47 [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x].
  • 7Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, AskariF, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellularcarcinoma surveillance in patients with cirrhosis. Cancer EpidemiolBiomarkers Prev 2012; 21: 793-799 [PMID: 22374994 DOI:10.1158/1055-9965.EPI-11-1005].
  • 8Kim do Y, Han KH. Epidemiology and surveillance ofhepatocellular carcinoma. Liver Cancer 2012; 1: 2-14 [PMID:24159567 DOI: 10.1159/000339016].
  • 9Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, DebuireB. New perspectives and strategy research biomarkers forhepatocellular carcinoma. Clin Chem Lab Med 2007; 45: 1169-1179[PMID: 17635075 DOI: 10.1515/CCLM.2007.262].
  • 10Bruix J, Sherman M. Management of hepatocellular carcinoma.Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933].

共引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部